Pfizer’s anti-Covid pill can be made by Indian drug firms without royalties

Pfizer’s anti-Covid pill can be made by Indian drug firms without royalties
Share This :



Generic drug manufacturers in India, among a total of 95 low- and middle- income countries, will be allowed to sell Pfizer’s experimental anti-viral Covid pill, the pharma major said on Tuesday.


“Under the terms of the head license agreement between and MPP (medicines patent pool), qualified generic medicine manufacturers worldwide that are granted sub-licenses will be able to supply PF-07321332 in combination with ritonavir to 95 countries, including India,” a spokesperson told Business Standard.





The pharma company will not receive royalties on sales in low-income countries and will further waive royalties on sales in all countries covered by the MPP agreement while Covid-19 remains classified as a Public Health Emergency of International Concern by the World Health Organization.


During its Phase-2 and 3 study, found that, when co-administered with a low dose of ritonavir, the scheduled interim analysis showed an 89 per cent reduction in risk of Covid-19-related hospitalization or death as compared to those who were given a placebo.


“We plan to submit data from the interim analysis of the Phase 2/3 study as part of its ongoing rolling submission to the US FDA for Emergency Use Authorization (EUA) as soon as possible. We have also initiated rolling submissions in several other countries. However we cannot speculate on the regulatory timelines,” the company spokesperson said.


Reuters reported on Monday that Dr Reddy’s Laboratories, one of a handful of Indian drug companies licensed to make a new Covid-19 pill developed by Merck, said it was open to making the similar pill from Pfizer, thought to be even more effective.

, Pfizer’s anti-Covid pill can be made by Indian drug firms without royalties, Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor





Source link

Share This :